Historical aspects of chirality of drugs

V. V. Shmatenko

Abstract


Currently only about 15% of all pharmaceutical products synthesized are presented by pure enantiomers.Many medicines exist as a mixture of two, and often a larger number of spatial isomers with a different biological activity. Optical isomers have different biological, pharmacological and technological properties. The optical activity, odor, toxicity, pharmacodynamic, pharmacokinetic and technological properties depend on chirality of the same substance. This led to the study of important aspects of the theory of chirality when creating medicines. The article considers historical aspects of chirality of drugs. Based on the library analysis the mandatory consideration of the chemical nature of chirality of drugs in production of pharmaceuticals, as well as the necessity of the preclinical and clinical trials of drugs have been substantiated. It has been found that creation of pure chiral drugs is a promising research direction. Its introduction into clinical practice allows, firstly, to use lower
doses of drugs without the loss of efficiency, and secondly, to improve the safety and reduce the risk of adverse reactions during therapy.


Keywords


drugs; chirality; historical aspects; enantiomers; optical rotation

References


Черних В. П. Органічна хімія / В. П. Черних. – Режим доступу: http://kingmed.info/knigi/Himiya/book_292/Organichna_himiya-Chernih_VP-2004-djvu.

Биологическая активность энантиомеров: хиральный переход. – Режим доступу: http://studopedia.ru/4_8292_razrabotkalekarstv-na-baze-soedineniy-liderov.html.

Марино П. Интенсивная терапия / пер. с англ. – М.: ГЭОТАР-Медиа, 2010. – 768 с.

Борисенко Т. А. Фармацевтична розробка поліелектролітних інфузійних розчинів з глюкозою та малат-іонами: автореферат … канд. фарм. н. – К., 2010. – 20 с.

Лекарства хиральные. – Режим доступу: http://chem21.info/info/318809.

Оптическая изомерия: новое слово в кардиологии. – Режим доступу: http:// health-ua.com/article/2462.html.

ESC Guidelines for the Management of Stable Angina Pectoris // Eur. Heart J. – 2006. – Vol. 27. – P. 1341-1381.

Guidelines for the management of arterial hypertension // J. Hypertension. – 2007. – Vol. 25. – P. 1105-1187.

MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure // JAMA. – 2000. – Vol. 283. – P. 1295-1302.

Mehvar R. Stereo specific pharmacokinetics and pharmacodynamics of b-adrenergic blockers in humans / R. Mehvar, D. Brocks // J. Pharm. Pharmaceut. Sci. – 2001. – Vol. 4. – P. 185-200.

Aneja P. Comparative clinical study of efficacy and safety of S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stableangina / P. Aneja, A. Srinivas, A. Das Biswas // Intern. J. Clin. Pharm. Therap. – 2007. – Vol. 45. – P. 253-258.

Jayaram S. The SMART Trial: S-metoprolol Assessment in Hypertension Trial / S. Jayaram, U. Kaul, V. Pai et al. // Cardiology Today. – 2005. – Vol. 9. – P. 222-229.

Фармацевтичні та медико-біологічні аспекти ліків [текст]: навч. посiб. для студ., магістрів, асп., викл., наук. співроб. та спеціалістів фармації / І. М. Перцев, О. Х. Пімінов, М. М. Слободянюк [та ін.]; за ред. І. М. Перцева. – 2-ге вид., перероб. та доп. – Вінниця : Нова Книга, 2007. – 725 с.


GOST Style Citations


1. Chernykh V. P. Orhanіchna khіmіya / V. P. Chernykh. – Available from: http:// kingmed.info/knigi/Himiya/book_292/Organichna_himiya Chernih_VP-2004-djvu.

2. Biologicheskaya aktivnost’ ehnantiomerov: hiral’niy perekhod. – Available from: http://studopedia.ru/4_8292_razrabotkalekarstv-na-baze-soedineniy-liderov.html.

3. Marino P. Intensivnaya terapiya: Per. s angl. – M.: GEHOTAR-Media, 2010. – 768 p.

4. Borisenko T. A. Farmatsevtychna rozrobka polіelektrolіtnykh іnfuzіynykh rozchynіv z glyukozoyu ta malat-іonamy. Avtoreferat k. farm. n., Kyiv. – 2010. – 20 p.

5. Lekarstva hiral’nye. – Available from: http://chem21.info/info/318809/.

6. Opticheskaya izomeriya: novoe slovo v kardiologii. – Available from: http://healthua.com/article/2462.html.

7. ESC Guidelines for the Management of Stable Angina Pectoris // Eur. Heart J. – 2006. – Vol. 27. – P. 1341-1381.

8. Guidelines for the management of arterial hypertension // J. Hypertension. – 2007. – Vol. 25. – P. 1105-1187.

9. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure // JAMA. – 2000. – Vol. 283. – P. 1295-1302.

10. Mehvar R., Brocks D. Stereo specific pharmacokinetics and pharmacodynamics of β-adrenergic blockers in humans // J. Pharm. Pharmaceut. Sci. – 2001. – Vol. 4. – P. 185-200.

11. Aneja P., Srinivas A., Das Biswas A. A comparative clinical study of efficacy and safety of S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stableangina // Intern. J. Clin. Pharm. Therap. – 2007. – Vol. 45. – P. 253-258.

12. Jayaram S., Kaul U., Pai V. et al. The SMART Trial: S-metoprolol Assessment in Hypertension Trial //Cardiology Today. – 2005. – Vol. 9. – P. 222-229.

13. Farmacevtychnі ta medyko-bіolohіchnі aspekty lіkіv [Tekst]: navch. posib. dlya stud., magіstrіv, asp., vykl., nauk. spіvrob. ta spetsіalіstіv farmatsіi / І. M. Pertsev, O. Kh. Pіmіnov, M. M. Slobodyanyuk [ta іn.]; za red. І. M. Pertsev ; NUPh. – 2 vid., pererob. ta dop. – Vіnnytsya: N. Kn., 2007. – 725 p.





DOI: https://doi.org/10.24959/sphhcj.16.32

Abbreviated key title: Soc. farm. ohor. zdor.

ISSN 2518-1564 (Online), ISSN 2413-6085 (Print)